Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer

Shi, Liu; Chevolot, Yann; Souteyrand, Éliane; Laurenceau, Emmanuelle

doi:10.3233/cbm-160117

Cited by 13 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated HSP can stimulate the immune system to produce anti-HSP autoantibodies (AAbs). AAbs against HSPs have been identified in the circulation of various cancer patients [156]. Because of their specificity and stability in the sera, AAbs against HSPs can be also attractive biomarkers for the development of less invasive serological tests for the diagnosis and the prognosis of cancer.…”

Section: Hsps As Biomarkers Detectable By Liquid Biopsiesmentioning

confidence: 99%

Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion

Taha

Ono

Eguchi

2019

IJMS

154

139

View full text Add to dashboard Cite

Extracellular heat shock proteins (ex-HSPs) have been found in exosomes, oncosomes, membrane surfaces, as well as free HSP in cancer and various pathological conditions, also known as alarmins. Such ex-HSPs include HSP90 (α, β, Gp96, Trap1), HSP70, and large and small HSPs. Production of HSPs is coordinately induced by heat shock factor 1 (HSF1) and hypoxia-inducible factor 1 (HIF-1), while matrix metalloproteinase 3 (MMP-3) and heterochromatin protein 1 are novel inducers of HSPs. Oncosomes released by tumor cells are a major aspect of the resistance-associated secretory phenotype (RASP) by which immune evasion can be established. The concepts of RASP are: (i) releases of ex-HSP and HSP-rich oncosomes are essential in RASP, by which molecular co-transfer of HSPs with oncogenic factors to recipient cells can promote cancer progression and resistance against stresses such as hypoxia, radiation, drugs, and immune systems; (ii) RASP of tumor cells can eject anticancer drugs, targeted therapeutics, and immune checkpoint inhibitors with oncosomes; (iii) cytotoxic lipids can be also released from tumor cells as RASP. ex-HSP and membrane-surface HSP (mHSP) play immunostimulatory roles recognized by CD91+ scavenger receptor expressed by endothelial cells-1 (SREC-1)+ Toll-like receptors (TLRs)+ antigen-presenting cells, leading to antigen cross-presentation and T cell cross-priming, as well as by CD94+ natural killer cells, leading to tumor cytolysis. On the other hand, ex-HSP/CD91 signaling in cancer cells promotes cancer progression. HSPs in body fluids are potential biomarkers detectable by liquid biopsies in cancers and tissue-damaged diseases. HSP-based vaccines, inhibitors, and RNAi therapeutics are also reviewed.

show abstract

Section: Hsps As Biomarkers Detectable By Liquid Biopsiesmentioning

confidence: 99%

Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion

Taha

Ono

Eguchi

2019

IJMS

154

139

View full text Add to dashboard Cite

show abstract

“…HSPs have anti-apoptotic properties and can help cancer cells evade apoptosis. Accordingly, they are overexpressed in a wide range of cancers, and this overexpression is a bad prognostic marker for some cancers [ 102 , 103 ]. Moreover, these molecules are shown to be involved in ICD.…”

Section: Origins Of Autoimmune Responses In Oncologymentioning

confidence: 99%

“…These aAbs are also observed in a wide range of autoimmune diseases including SLE and RA [ 86 ]. Anti-HSP90 aAbs in breast cancer patients are associated with a bad prognosis [ 103 ]. It was shown that an aAb against a single HSP was present in between 8%–40% of cancer patients as opposed to 1.6–25% of healthy subjects [ 103 ].…”

Section: Origins Of Autoimmune Responses In Oncologymentioning

confidence: 99%

Autoimmune Responses in Oncology: Causes and Significance

Bareke

Juanes-Velasco

Landeira-Viñuela

et al. 2021

IJMS

View full text Add to dashboard Cite

Specific anti-tumor immune responses have proven to be pivotal in shaping tumorigenesis and tumor progression in solid cancers. These responses can also be of an autoimmune nature, and autoantibodies can sometimes be present even before the onset of clinically overt disease. Autoantibodies can be generated due to mutated gene products, aberrant expression and post-transcriptional modification of proteins, a pro-immunogenic milieu, anti-cancer treatments, cross-reactivity of tumor-specific lymphocytes, epitope spreading, and microbiota-related and genetic factors. Understanding these responses has implications for both basic and clinical immunology. Autoantibodies in solid cancers can be used for early detection of cancer as well as for biomarkers of prognosis and treatment response. High-throughput techniques such as protein microarrays make parallel detection of multiple autoantibodies for increased specificity and sensitivity feasible, affordable, and quick. Cancer immunotherapy has revolutionized cancer treatments and has made a considerable impact on reducing cancer-associated morbidity and mortality. However, immunotherapeutic interventions such as immune checkpoint inhibition can induce immune-related toxicities, which can even be life-threatening. Uncovering the reasons for treatment-induced autoimmunity can lead to fine-tuning of cancer immunotherapy approaches to evade toxic events while inducing an effective anti-tumor immune response.

show abstract

“…Antibodies against HSPs are normally present in the serum of healthy individuals (Cohen ; Shi et al . ). The increased anti‐HspBP1 IgG levels observed in the present study may be associated with B cell activation because of the increased serum level of HspBP1.…”

Section: Discussionmentioning

confidence: 97%

Hsp BP 1 and anti‐Hsp BP 1 levels in the serum of HIV ‐infected individuals are associated to the disease progression

Ceccin¹,

Souza

Hilario

et al. 2019

J of Applied Microbiology

View full text Add to dashboard Cite

Aims The objective of this research was to quantify the levels of circulating HspBP1 and anti‐HspBP1 IgG in HIV‐infected individuals and to correlate them with CD4 T cell counts and viral load, as well as to determine the kinetics of those proteins during acute phase. Methods and Results Sixty serum samples from HIV‐positive outpatients, thirty with high viral load and thirty with low viral load were analysed. The HspBP1 and anti‐HspBP1 were quantified by ELISA. To investigate the kinetic of HspBP1 and anti‐HspBp1 during the acute phase, these proteins and antibodies were quantified in samples of a commercial seroconverting HIV panel. All dosages were compared with the CD4 and CD8 T cell counts and HIV viral load. The results indicated that HIV positive outpatients presented significant increase in HspBP1 and anti‐HspBP1 serum levels, compared with uninfected healthy. HspBP1 and anti‐HspBP1 were negatively correlated with CD4 counts and CD4:CD8 ratio. In the acute phase, HspBP1 became significantly elevated 15 days after HIV infection. Conclusions These results indicate that the quantification of HspBP1 can be associated to others well‐established parameters of the HIV progression. Significance and Impact of the Study The discovery that HspBp1 and anti‐HspBp1 are associated with progression of HIV infection is new and corroborates to validate the quantification of these proteins as an additional strategy in the management of the HIV infection.

show abstract

Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer

Cited by 13 publications

References 47 publications

Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion

Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion

Autoimmune Responses in Oncology: Causes and Significance

Hsp BP 1 and anti‐Hsp BP 1 levels in the serum of HIV ‐infected individuals are associated to the disease progression

Contact Info

Product

Resources

About